Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.74M Buy
7,992
+171
+2% +$37.9K 0.21% 54
2025
Q4
$1.79M Buy
7,821
+134
+2% +$30.5K 0.22% 51
2025
Q3
$1.78M Buy
7,687
+636
+9% +$130K 0.23% 45
2025
Q2
$1.31M Buy
7,051
+245
+4% +$45.5K 0.19% 51
2025
Q1
$1.43M Buy
6,806
+619
+10% +$120K 0.26% 43
2024
Q4
$1.1M Buy
6,187
+482
+8% +$88.6K 0.2% 54
2024
Q3
$1.13M Buy
5,705
+942
+20% +$176K 0.21% 57
2024
Q2
$817K Sell
4,763
-136
-3% -$22.5K 0.17% 67
2024
Q1
$892K Buy
4,899
+736
+18% +$127K 0.19% 62
2023
Q4
$645K Sell
4,163
-694
-14% -$101K 0.17% 65
2023
Q3
$724K Sell
4,857
-149
-3% -$21.9K 0.21% 47
2023
Q2
$674K Sell
5,006
-3,252
-39% -$477K 0.22% 51
2023
Q1
$1.32M Buy
8,258
+364
+5% +$55.6K 0.4% 29
2022
Q4
$1.28M Buy
7,894
+506
+7% +$77.6K 0.37% 35
2022
Q3
$992K Sell
7,388
-236
-3% -$33.9K 0.3% 36
2022
Q2
$1.17M Buy
7,624
+102
+1% +$15.6K 0.33% 32
2022
Q1
$1.22M Buy
7,522
+1,060
+16% +$154K 0.31% 38
2021
Q4
$875K Buy
6,462
+757
+13% +$89.4K 0.26% 53
2021
Q3
$615K Buy
5,705
+301
+6% +$34.4K 0.21% 60
2021
Q2
$609K Buy
5,404
+409
+8% +$46.1K 0.2% 58
2021
Q1
$541K Buy
4,995
+234
+5% +$25K 0.22% 57
2020
Q4
$510K Buy
+4,761
New +$458K 0.21% 58

Other funds holding ABBV

MJP Associates's ABBV Position: Q1 2026 in Review

MJP Associates increased its AbbVie (ABBV) stake by 2.2% in Q1 2026, buying an estimated $37.9K and bringing the position to 7,992 shares worth $1.74M. The position accounts for 0.21% of the portfolio, ranked #54.

MJP Associates first reported a position in ABBV in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.79M in Q4 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • MJP Associates held 7,992 shares of AbbVie worth $1.74M as of Q1 2026.
  • MJP Associates bought 171 AbbVie shares in Q1 2026, an estimated $37.9K.
  • AbbVie made up 0.21% of MJP Associates's portfolio in Q1 2026, its #54 holding.
  • MJP Associates first reported a position in AbbVie in Q4 2020 and has held it in 22 quarters since.
  • MJP Associates's AbbVie position peaked at $1.79M in Q4 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on MJP Associates's 13F filing for Q1 2026, filed 5 May 2026.